A long-term open-label safety study of galcanezumab in Japanese patients with migraine.
Hirata K, Takeshima T, Sakai F, Tatsuoka Y, Suzuki N, Igarashi H, Nakamura T, Ozeki A, Yamazaki H, Skljarevski V.
Hirata K, et al. Among authors: igarashi h.
Expert Opin Drug Saf. 2021 Jun;20(6):721-733. doi: 10.1080/14740338.2021.1866536. Epub 2021 Jan 4.
Expert Opin Drug Saf. 2021.
PMID: 33393835
Clinical Trial.